Ivax/Nycomed merger off: replaced by marketing alliance in U.S. and Europe.
IVAX TO MARKET NYCOMED's NSAID LORNOXICAM: MERGER AGREEMENT OFF, the companies announced Nov. 15. Hafslund Nycomed will license North American rights to its non-steroidal anti-inflammatory agent for moderately severe pain to Ivax as part of a broad marketing alliance between the two firms. An NDA for lornoxicam has been filed, according to Nycomed materials distributed at a recent Oppenheimer & Co. conference in New York City. Ivax will also gain rights to Nycomed's hybrid toxin to treat brain tumors.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth